Kinetics of stem cell engraftment and clearance of leukaemia cells after allogeneic stem cell transplantation with reduced intensity conditioning in chronic myeloid leukaemia

European Journal of Haematology

Volumn 69, Issue 1, 2002, Pages 7-10

  Kreuzer, Karl Anton ^a   Schmidt, Christian Andreas ^a   Schetelig, Johannes ^a   Held, Thomas K ^a   Thiede, Christian ^b   Ehninger, Gerhard ^b   Siegert, Wolfgang ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

bcr abl fusion transcripts; Chronic myeloid leukaemia; Haematopoietic chimerism; Nonmyeloablative stem cell transplantation

Indexed keywords

BCR ABL PROTEIN; BUSULFAN; FLUDARABINE; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CANCER REGRESSION; CELL KINETICS; CHIMERA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONDITIONING; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; LEUKEMIA CELL; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; STEM CELL TRANSPLANTATION; TIME SERIES ANALYSIS; TRANSCRIPTION REGULATION; TREATMENT OUTCOME;

ADULT; CELL SURVIVAL; FEMALE; GENES, ABL; GRAFT SURVIVAL; HUMANS; KINETICS; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; STEM CELL TRANSPLANTATION; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 0036660181     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2002.01761.x     Document Type: Article

References (9)

1. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998;91:756-763.
2. Khouri IF, Keating M, Körbling M, et al. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998;16: 2817-2824.
3. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997;89:4531-4536.
4. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000;343:750-758.
5. McSweeney PA, Storb R. Mixed chimerism: preclinical and clinical applications. Biol Blood Marrow Transplantation 1999;5:192-203.
6. Deane M, Koh M, Foroni L, et al. FLAG-idarubicin and allogeneic stem cell transplantation for pH-positive ALL beyond first remission. Bone Marrow Transplantation 1998;22:1137-1143.
7. Kreuzer KA, Lass U, Bohn A, et al. LightCycler technology for the quantitation of bcr/abl fusion transcripts. Cancer Res 1999;59:3171-3174.
8. Kreuzer KA, Lass U, Landt O, et al. Highly sensitive and specific fluorescence RT-PCR assay for the pseudogene free detection of beta-actin transcripts as quantitative reference. Clin Chem 1999;45:297-300.
9. Thiede C, Florek M, Bornhäuser M, et al. Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection. Bone Marrow Transplant 1999;23:1055-1060.